Millennium Management LLC Has $18.81 Million Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Millennium Management LLC grew its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 34.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 958,852 shares of the company’s stock after acquiring an additional 244,981 shares during the quarter. Millennium Management LLC owned about 3.20% of Fulgent Genetics worth $18,813,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of FLGT. Divisadero Street Capital Management LP increased its holdings in Fulgent Genetics by 46.4% during the 2nd quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock worth $9,912,000 after purchasing an additional 160,212 shares in the last quarter. Park West Asset Management LLC grew its holdings in Fulgent Genetics by 23.1% during the fourth quarter. Park West Asset Management LLC now owns 424,783 shares of the company’s stock worth $12,280,000 after buying an additional 79,649 shares in the last quarter. Bank of New York Mellon Corp raised its position in Fulgent Genetics by 37.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 201,201 shares of the company’s stock valued at $3,948,000 after buying an additional 55,020 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Fulgent Genetics by 593.5% during the 2nd quarter. Acadian Asset Management LLC now owns 62,724 shares of the company’s stock valued at $1,227,000 after acquiring an additional 53,680 shares in the last quarter. Finally, Acuitas Investments LLC purchased a new position in Fulgent Genetics during the 2nd quarter worth $962,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Price Performance

NASDAQ FLGT opened at $20.89 on Friday. The company has a fifty day moving average price of $22.64 and a 200-day moving average price of $21.59. Fulgent Genetics, Inc. has a 1 year low of $18.91 and a 1 year high of $30.68. The firm has a market cap of $625.11 million, a price-to-earnings ratio of -3.75 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings data on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The business had revenue of $71.03 million during the quarter, compared to the consensus estimate of $69.07 million. During the same period in the prior year, the firm posted ($0.33) EPS. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, research analysts anticipate that Fulgent Genetics, Inc. will post -1.46 EPS for the current fiscal year.

Insider Activity

In related news, CEO Ming Hsieh sold 2,313 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the transaction, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 4,324 shares of company stock valued at $98,717 in the last ninety days. 31.76% of the stock is currently owned by insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.